Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer

Günel, Tuba; Gumusoglu‐Acar, Ece; Dogan, Berkcan; Ertem, Fatma Betül; Hosseini, Mohammad Kazem; Cevik, Nazife; Şenol, Taylan; Topuz, Samet; Aydınlı, Kılıç

doi:10.1007/s00404-018-4913-3

Cited by 19 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study by Jia et al reported the tumor suppressive role of miR-34 in regulation of tumor proliferation via inducting autophagy and apoptosis and suppression of cell invasion by targeting Notch 1 (Jia et al, 2019, p. 1). Wang et al utilizing integrated meta-analysis approach Merritt et al, 2008;Faggad et al, 2010;Pampalakis et al, 2010 let-7i, miR-221,−30c,−152 and−193 miR-185,−106a,−181a, −210,−423,−103 Cochrane et al, 2009;Hu et al, 2009 miRs 100, 199a, 200a, and 214 Upregulated Gong et al, 2016Gong et al, (hsa-miR-135, 150,−340, 625, 1908 Günel et al, 2018 have shown the oncogenic role of miRNA-27a by mediating FOXO1 and its inhibition could serve as a new strategy in combating ovarian cancer (Wang Z. et al, 2018, p. 1). Hu et al identified miR-934 as an oncogene in OC by directly targeting BRMS1L, and thus could serve as a therapeutic marker (Hu et al, 2019).…”

Section: Chemoresistancementioning

confidence: 99%

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

Singh

Gupta

Sachan

2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Ovarian cancer (OC) causes significant morbidity and mortality as neither detection nor screening of OC is currently feasible at an early stage. Difficulty to promptly diagnose OC in its early stage remains challenging due to non-specific symptoms in the early-stage of the disease, their presentation at an advanced stage and poor survival. Therefore, improved detection methods are urgently needed. In this article, we summarize the potential clinical utility of epigenetic signatures like DNA methylation, histone modifications, and microRNA dysregulation, which play important role in ovarian carcinogenesis and discuss its application in development of diagnostic, prognostic, and predictive biomarkers. Molecular characterization of epigenetic modification (methylation) in circulating cell free tumor DNA in body fluids offers novel, non-invasive approach for identification of potential promising cancer biomarkers, which can be performed at multiple time points and probably better reflects the prevailing molecular profile of cancer. Current status of epigenetic research in diagnosis of early OC and its management are discussed here with main focus on potential diagnostic biomarkers in tissue and body fluids. Rapid and point of care diagnostic applications of DNA methylation in liquid biopsy has been precluded as a result of cumbersome sample preparation with complicated conventional methods of isolation. New technologies which allow rapid identification of methylation signatures directly from blood will facilitate sample-to answer solutions thereby enabling next-generation point of care molecular diagnostics. To date, not a single epigenetic biomarker which could accurately detect ovarian cancer at an early stage in either tissue or body fluid has been reported. Taken together, the methodological drawbacks, heterogeneity associated with ovarian cancer and non-validation of the clinical utility of reported potential biomarkers in larger ovarian cancer populations has impeded the transition of epigenetic biomarkers from lab to clinical settings. Until addressed, clinical implementation as a diagnostic measure is a far way to go.

show abstract

Section: Chemoresistancementioning

confidence: 99%

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

Singh

Gupta

Sachan

2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Serum lactate dehydrogenase has also been shown to act as a significant marker of head and neck squamous cell carcinoma, and Epstein‐Barr virus (EBV) DNAs or miRNAs are significantly correlated with distant metastasis and death in patients with NPC . Serum hsa‐miR‐1273 g‐3p might also have potential applications as both a prognostic and diagnostic biomarker of recurrent epithelial ovarian cancer . Squamous cell carcinoma antigen, a marker of squamous cell carcinoma, can be used to detect head and neck cancers .…”

Section: Introductionmentioning

confidence: 99%

“…[12][13][14][15][16][17][18] Serum hsa-miR-1273 g-3p might also have potential applications as both a prognostic and diagnostic biomarker of recurrent epithelial ovarian cancer. 19 Squamous cell carcinoma antigen, a marker of squamous cell carcinoma, can be used to detect head and neck cancers. 20 However, there are clear limitations to the use of these biomarkers.…”

mentioning

confidence: 99%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

View full text Add to dashboard Cite

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

show abstract

“…MiR-486-5p was upregulated and promoted the proliferation and migration of endometriosis-associated OC cells (84). Moreover, miRNA microarray analysis indicated that hsa-miR-1273g-3p was downregulated in recurrent EOC serum samples versus healthy control serum samples (85). The circulating hsa-miR-1273g-3p level could potentially distinguish recurrent EOC patients from healthy controls (85).…”

Section: Mirna Microarraysmentioning

confidence: 97%

“…Moreover, miRNA microarray analysis indicated that hsa-miR-1273g-3p was downregulated in recurrent EOC serum samples versus healthy control serum samples (85). The circulating hsa-miR-1273g-3p level could potentially distinguish recurrent EOC patients from healthy controls (85). Another study demonstrated that higher expression of 33 miRNAs and lower expression of 18 miRNAs were found in recurrent EOC than in primary EOC by miRNA microarray (86).…”

Section: Mirna Microarraysmentioning

confidence: 99%

Applications of Multi-omics Approaches for Exploring the Molecular Mechanism of Ovarian Carcinogenesis

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer ranks as the fifth most common cause of cancer-related death in females. The molecular mechanisms of ovarian carcinogenesis need to be explored in order to identify effective clinical therapies for ovarian cancer. Recently, multi-omics approaches have been applied to determine the mechanisms of ovarian oncogenesis at genomics (DNA), transcriptomics (RNA), proteomics (proteins), and metabolomics (metabolites) levels. Multi-omics approaches can identify some diagnostic and prognostic biomarkers and therapeutic targets for ovarian cancer, and these molecular signatures are beneficial for clarifying the development and progression of ovarian cancer. Moreover, the discovery of molecular signatures and targeted therapy strategies could noticeably improve the prognosis of ovarian cancer patients.

show abstract

Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer

Cited by 19 publications

References 27 publications

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Applications of Multi-omics Approaches for Exploring the Molecular Mechanism of Ovarian Carcinogenesis

Contact Info

Product

Resources

About